# Camrelizumab Combined With Apatinib Mesylate

> **NCT05380986** · NA · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Camrelizumab combined with apatinib mesylate

## Key facts

- **NCT ID:** NCT05380986
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-20
- **Primary completion:** 2024-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05380986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05380986, "Camrelizumab Combined With Apatinib Mesylate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05380986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*